Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
Collection of Biological Samples for Research Purposes: Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
30 participants
Jan 13, 2026
INTERVENTIONAL
Conditions
Summary
The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.
Eligibility
Inclusion Criteria10
- / Control Group
- Age ≥ 60 years;
- Scheduled for cardiac surgery involving sternotomy;
- Normal blood count within the two months preceding sampling;
- Affiliated with, or beneficiary of, a social security system;
- Written informed consent to participate in the study.
- Age ≥ 60 years;
- Diagnosis of de novo AML or AML secondary to myelodysplastic syndrome, scheduled to receive azacitidine-based treatment;
- Affiliated with, or beneficiary of, a social security system;
- Written informed consent to participate in the study.
Exclusion Criteria12
- Patients deemed unsuitable for sampling by the surgeon performing the procedure;
- Patients under legal protection measures;
- Patients under judicial supervision or deprived of liberty by judicial or administrative decision;
- Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV).
- / AML Group
- Diagnosis of a hematologic disease other than AML;
- Clinical signs suggestive of active central nervous system leukemia, or presence of isolated extramedullary leukemia;
- Previous treatment for AML other than hydroxyurea;
- Severe comorbidities that could interfere with the study, as assessed by the principal investigator;
- Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV);
- Patients under legal protection;
- Patients under judicial supervision or deprived of liberty by judicial or administrative decision.
Interventions
Methylation profiles will be analyzed and DNA regions (CpG sites) that show significant differences between healthy and pathological cells from bone marrow will be identified. These regions could serve as epigenetic markers for cells from patients with LAM, if they can be used by digital PCR. These differentially methylated CpG islands will be targeted for the design of specific primer and probe pairs for use in digital PCR. The markers will then be tested in circulating free DNA from blood.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07250217